Prostate oncology patient

The Linkou Chang Gung Memorial Hospital Urologic Oncology Team has managed ~400 new prostate cancer cases annually since 2016. In 2020, cases declined to 386 due to COVID-19, but exceeded 600 per year after 2022. Our multidisciplinary center provides patient-centered, personalized, and adaptive systemic care.

• MRI–US fusion biopsy improves accuracy, reduces transrectal biopsy risks, and shortens time to treatment.

• Post-RARP cystography predicts incontinence and guides personalized rehab and medication.

• Multidisciplinary care expedites PSMA PET/CT and therapy.

• We lead Taiwan’s only da Vinci prostate surgery training center.

• 4,776 cases, No.1 in Taiwan.

• da Vinci avg 45/month, No.1 in Taiwan.

• Established the Proton and Radiation Therapy Center in 2015, +25~40%.

• PSMA PET workflow, No.1.

• Most prostate CA papers in Taiwan.

• MRI fusion biopsy achieves the highest diagnostic rate for small lesions.

• PSMA scanning increases the detection rate of recurrence.

• Photon, proton, and CyberKnife treatments have the highest number of cases nationwide.

• The results of da Vinci surgical treatment show that the cohort has the lowest probability of biochemical recurrence and the fastest recovery rate from urinary incontinence.

• For case management service indicators and outcomes, the patient retention rate is 92.9%.

• The combined effectiveness of photon and proton therapy shows a survival rate of 98%.

• SMI-UI incontinence management enhances self-training ability, resulting in high patient satisfaction.

• Healthcare staff satisfaction scores range from 96 to 98, with an overall inpatient satisfaction score of 90.

• Patients exhibit good psychological status, low PSA levels, and few symptoms.

• Professor Chun-Te Wu improved three-layer suturing technique and other latest technologies won the 2025 National Innovation Award.

• Professor Chun-Te Wu built a urinary incontinence prediction system, applied for a patent, and developed a mobile app.

• Professor Jacob See-Tong Pang serves as the President of the Urological Association of Asia (UAA) and hosted the 22nd UAA Congress in Taiwan in 2025.

• Integrate team-based care to create a comprehensive medical model.

• Innovate precise AI-assisted medical care, leading both domestically and internationally.

• Promote outstanding treatment outcomes, supported by data-driven evidence.

• Advocate for men's health awareness nationwide, fulfilling social responsibility.

• Cultivate medical talent and support collaborative research and clinical standard development in the Asia-Pacific region, establishing a benchmark center for prostate cancer treatment in Asia.